Go Pro
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel Free SBTX Stock Alerts

SkinBioTherapeutics (SBTX) Competitors

SkinBioTherapeutics logo
GBX 11.25 -0.89 (-7.29%)
As of 12:46 PM Eastern
Compare

SBTX vs. TILS, VSN, BVXP, MPH, and 4BB

Should you buy SkinBioTherapeutics stock or one of its competitors? MarketBeat compares SkinBioTherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SkinBioTherapeutics include Tiziana Life Sciences (TILS), Verseon (VSN), Bioventix (BVXP), Mereo BioPharma Group plc (MPH.L) (MPH), and 4basebio (4BB). These companies are all part of the "biotechnology" industry.

How does SkinBioTherapeutics compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Tiziana Life Sciences has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. Tiziana Life Sciences' return on equity of 0.00% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
SkinBioTherapeutics -8.73%-5.25%-61.18%

3.0% of SkinBioTherapeutics shares are held by institutional investors. 2.7% of SkinBioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tiziana Life Sciences has higher earnings, but lower revenue than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A
SkinBioTherapeutics£4.64M6.29-£3.71M-£0.31N/A

In the previous week, Tiziana Life Sciences had 1 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 1 mentions for Tiziana Life Sciences and 0 mentions for SkinBioTherapeutics. Tiziana Life Sciences' average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.

Company Overall Sentiment
Tiziana Life Sciences Neutral
SkinBioTherapeutics Neutral

Summary

Tiziana Life Sciences beats SkinBioTherapeutics on 5 of the 9 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Verseon?

Verseon (LON:VSN) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

3.0% of SkinBioTherapeutics shares are held by institutional investors. 2.7% of SkinBioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Verseon has higher earnings, but lower revenue than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VerseonN/AN/AN/A-£14.30N/A
SkinBioTherapeutics£4.64M6.29-£3.71M-£0.31N/A

In the previous week, Verseon's average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.

Company Overall Sentiment
Verseon Neutral
SkinBioTherapeutics Neutral

Verseon has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. Verseon's return on equity of 0.00% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
VerseonN/A N/A N/A
SkinBioTherapeutics -8.73%-5.25%-61.18%

Summary

Verseon and SkinBioTherapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Bioventix?

Bioventix (LON:BVXP) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Bioventix has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioventix£12.54M6.73£8.12M£140.5211.49
SkinBioTherapeutics£4.64M6.29-£3.71M-£0.31N/A

Bioventix has a net margin of 59.30% compared to SkinBioTherapeutics' net margin of -8.73%. Bioventix's return on equity of 65.83% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bioventix59.30% 65.83% 54.07%
SkinBioTherapeutics -8.73%-5.25%-61.18%

20.6% of Bioventix shares are held by institutional investors. Comparatively, 3.0% of SkinBioTherapeutics shares are held by institutional investors. 6.2% of Bioventix shares are held by insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bioventix has a beta of 0.554, meaning that its share price is 45% less volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.121, meaning that its share price is 88% less volatile than the broader market.

In the previous week, Bioventix had 2 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 2 mentions for Bioventix and 0 mentions for SkinBioTherapeutics. Bioventix's average media sentiment score of 1.91 beat SkinBioTherapeutics' score of 0.00 indicating that Bioventix is being referred to more favorably in the media.

Company Overall Sentiment
Bioventix Very Positive
SkinBioTherapeutics Neutral

Summary

Bioventix beats SkinBioTherapeutics on 13 of the 13 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Mereo BioPharma Group plc (MPH.L)?

SkinBioTherapeutics (LON:SBTX) and Mereo BioPharma Group plc (MPH.L) (LON:MPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Mereo BioPharma Group plc (MPH.L) has lower revenue, but higher earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SkinBioTherapeutics£4.64M6.29-£3.71M-£0.31N/A
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A

Mereo BioPharma Group plc (MPH.L) has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SkinBioTherapeutics-8.73% -5.25% -61.18%
Mereo BioPharma Group plc (MPH.L) N/A N/A N/A

3.0% of SkinBioTherapeutics shares are held by institutional investors. 2.7% of SkinBioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, SkinBioTherapeutics' average media sentiment score of 0.00 equaled Mereo BioPharma Group plc (MPH.L)'saverage media sentiment score.

Company Overall Sentiment
SkinBioTherapeutics Neutral
Mereo BioPharma Group plc (MPH.L) Neutral

Summary

SkinBioTherapeutics and Mereo BioPharma Group plc (MPH.L) tied by winning 4 of the 8 factors compared between the two stocks.

How does SkinBioTherapeutics compare to 4basebio?

SkinBioTherapeutics (LON:SBTX) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

SkinBioTherapeutics has a beta of 0.121, meaning that its stock price is 88% less volatile than the broader market. Comparatively, 4basebio has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

3.0% of SkinBioTherapeutics shares are owned by institutional investors. Comparatively, 0.9% of 4basebio shares are owned by institutional investors. 2.7% of SkinBioTherapeutics shares are owned by company insiders. Comparatively, 12.1% of 4basebio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

4basebio has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. SkinBioTherapeutics' return on equity of -5.25% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
SkinBioTherapeutics-8.73% -5.25% -61.18%
4basebio N/A -231.29%-54.30%

SkinBioTherapeutics has higher revenue and earnings than 4basebio. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SkinBioTherapeutics£4.64M6.29-£3.71M-£0.31N/A
4basebio£1.69M45.78-£9.84M-£109.00N/A

In the previous week, 4basebio had 1 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 1 mentions for 4basebio and 0 mentions for SkinBioTherapeutics. SkinBioTherapeutics' average media sentiment score of 0.00 equaled 4basebio'saverage media sentiment score.

Company Overall Sentiment
SkinBioTherapeutics Neutral
4basebio Neutral

4basebio has a consensus target price of GBX 1,400, indicating a potential upside of 179.72%. Given 4basebio's stronger consensus rating and higher probable upside, analysts plainly believe 4basebio is more favorable than SkinBioTherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SkinBioTherapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

4basebio beats SkinBioTherapeutics on 10 of the 15 factors compared between the two stocks.

Get SkinBioTherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SBTX vs. The Competition

Export
MetricSkinBioTherapeuticsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£29.16M£508.45M£6.85B£2.78B
Dividend YieldN/A3.87%2.66%6.14%
P/E Ratio-36.293.1126.04366.54
Price / Sales6.296,785.72550.3985,951.69
Price / Cash9.0013.1329.0927.87
Price / Book6.7089.3710.987.75
Net Income-£3.71M-£96.07M£3.57B£5.89B
7 Day Performance0.45%1.23%3.06%-1.01%
1 Month PerformanceN/A-0.19%0.72%-1.74%
1 Year Performance-33.04%74.49%36.82%65.54%

SkinBioTherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SBTX
SkinBioTherapeutics
N/AGBX 11.25
-7.3%		N/A-27.8%£29.16M£4.64MN/A11
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11
VSN
Verseon
N/AN/AN/AN/A£112.24MN/AN/AN/A
BVXP
Bioventix
N/AGBX 1,745
-4.4%		N/A-39.3%£91.18M£12.54M12.4212
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/AN/A50

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SBTX) was last updated on 6/29/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SpaceX is offering you shares. Don't take them.
SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel